US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
MSTR
$160.01
▲+0.00%
ASML
$1,867.31
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
MSTR
$160.01
▲+0.00%
ASML
$1,867.31
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Esperion Therapeutics, Inc. - Common Stock
(NQ:
ESPR
)
3.180
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Esperion Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
October 02, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
September 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
September 05, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
September 03, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
August 26, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 12, 2024
ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket
↗
August 12, 2024
Via
Benzinga
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 12, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 07, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Report Second Quarter 2024 Financial Results on August 12
July 25, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion to Participate in Upcoming BTIG Biotech Conference
July 24, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
July 16, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
June 28, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
↗
June 22, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024.
Via
Talk Markets
Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
↗
June 20, 2024
Via
Benzinga
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
↗
June 13, 2024
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy.
Via
InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 20, 2024
Via
Benzinga
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
↗
June 11, 2024
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential.
Via
InvestorPlace
Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
↗
June 07, 2024
Via
Benzinga
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
June 10, 2024
Via
Benzinga
Esperion to Participate in Upcoming June Investor Conferences
May 23, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
May 22, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
↗
May 20, 2024
Esperion Therapeutics and Otsuka Pharmaceutical report Phase 3 trial results for bempedoic acid in Japan, achieving significant LDL-C reduction in hypercholesterolemia patients. With no serious adverse...
Via
Benzinga
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
May 20, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
May 14, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 10, 2024
From
Esperion Therapeutics, Inc.
Via
GlobeNewswire
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
May 08, 2024
Via
AB Newswire
ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024
↗
May 07, 2024
ESPR stock results show that Esperion Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
↗
May 07, 2024
Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024...
Via
Benzinga
Why Is AgriFORCE Growing (AGRI) Stock Down 31% Today?
↗
May 07, 2024
AgriFORCE Growing stock is falling hard on Tuesday after the company announced an offering for AGRI shares from stockholders.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
